Fig. 1.

The CD8^HiIFNγ^HiCD33^LowFOXP3^Low immune profile is correlated with favorable clinical outcome. a,c Kaplan-Meier survival analysis of human sarcoma (a) and breast carcinoma (c) based on IFNγ gene copy number. The overall survival rates were stratified by IFNγ gene expression level: the 25% of patients with the highest IFNγ levels were placed in the IFNγ^Hi group and the 25% with the lowest IFNγ levels were placed in the IFNγ^Low group. b,d Patients with sarcoma (b) and patients with breast cancer d were grouped by IFNγ, CD8, CD33, and FOXP3 gene expression levels: the 25% of patients in the IFNγ^Hi group with the highest CD8a levels were placed in the CD8^HiIFNγ^Hi group, and the 25% of patients in the IFNγ^Low group with the lowest CD8a levels were placed in the CD8^LowIFNγ^Low group. The CD8^HiIFNγ^Hi group and the CD8^LowIFNγ^Low group were then substratified into the CD8^HiIFNγ^HiCD33^LowFOXP3^Low group, the CD8^HiIFNγ^HiCD33^HiFOXP3^Hi group, the CD8^LowIFNγ^LowCD33^LowFOXP3^Low group, and the CD8^LowIFNγ^LowCD33^HiFOXP3^Hi group. Kaplan-Meier analyses were used to determine the association of each group with a favorable survival outcome